JP2016519659A5 - - Google Patents

Download PDF

Info

Publication number
JP2016519659A5
JP2016519659A5 JP2016502225A JP2016502225A JP2016519659A5 JP 2016519659 A5 JP2016519659 A5 JP 2016519659A5 JP 2016502225 A JP2016502225 A JP 2016502225A JP 2016502225 A JP2016502225 A JP 2016502225A JP 2016519659 A5 JP2016519659 A5 JP 2016519659A5
Authority
JP
Japan
Prior art keywords
optionally substituted
use according
independently
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502225A
Other languages
English (en)
Japanese (ja)
Other versions
JP6579623B2 (ja
JP2016519659A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/026722 external-priority patent/WO2014151953A1/en
Publication of JP2016519659A publication Critical patent/JP2016519659A/ja
Publication of JP2016519659A5 publication Critical patent/JP2016519659A5/ja
Application granted granted Critical
Publication of JP6579623B2 publication Critical patent/JP6579623B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502225A 2013-03-15 2014-03-13 軟骨形成を誘導するための化合物及び方法 Active JP6579623B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361794094P 2013-03-15 2013-03-15
US61/794,094 2013-03-15
PCT/US2014/026722 WO2014151953A1 (en) 2013-03-15 2014-03-13 Compounds and methods for inducing chondrogenesis

Publications (3)

Publication Number Publication Date
JP2016519659A JP2016519659A (ja) 2016-07-07
JP2016519659A5 true JP2016519659A5 (enExample) 2017-04-13
JP6579623B2 JP6579623B2 (ja) 2019-09-25

Family

ID=51528123

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502225A Active JP6579623B2 (ja) 2013-03-15 2014-03-13 軟骨形成を誘導するための化合物及び方法

Country Status (10)

Country Link
US (3) US9452170B2 (enExample)
EP (1) EP2968330B1 (enExample)
JP (1) JP6579623B2 (enExample)
KR (1) KR102283996B1 (enExample)
CN (3) CN107007587A (enExample)
AU (1) AU2014236719B2 (enExample)
CA (1) CA2904160C (enExample)
ES (1) ES2900815T3 (enExample)
HK (1) HK1224172A1 (enExample)
WO (1) WO2014151953A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464065B2 (en) * 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US9452170B2 (en) 2013-03-15 2016-09-27 The California Institute For Biomedical Research Compounds and methods for inducing chondrogenesis
CN105294533A (zh) * 2015-12-02 2016-02-03 宋彤云 一种治疗骨病的药物组合物
KR20190084287A (ko) * 2016-11-14 2019-07-16 노파르티스 아게 연골 손상 및 관절염 치료 방법 및 조성물
KR20190137904A (ko) * 2017-04-24 2019-12-11 더 스크립스 리서치 인스티튜트 연골형성의 유도 방법
JOP20190282A1 (ar) * 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
CN107056677A (zh) * 2017-06-19 2017-08-18 常州大学 一种3‑烷基2,3‑二氢异吲哚啉酮衍生物的合成方法
CA3093551A1 (en) * 2018-03-29 2019-10-03 Elex Biotech, Inc. Compounds for treatment of cardiac arrhythmias and heart failure
CN110937987B (zh) * 2018-09-25 2022-09-06 深圳市灵兰生物医药科技有限公司 一种化合物的合成路线及在抗糖尿病药物制备领域的应用
WO2020080979A1 (en) * 2018-10-15 2020-04-23 Gero Discovery Limited Liability Company Pfkfb3 inhibitors and their uses
CN114105902B (zh) * 2018-12-28 2023-11-03 中山大学 噻唑苯甲酰胺衍生物及其在制备抗骨质疏松药物中的应用
CN112004798A (zh) * 2019-01-07 2020-11-27 江苏凯迪恩医药科技有限公司 一种苯甲酰胺类化合物、中间体、制备方法及应用
US12281060B2 (en) * 2019-04-02 2025-04-22 The University Of Chicago Remodilins for airway remodeling and organ fibrosis
AU2021321068B2 (en) * 2020-08-05 2025-01-02 Lg Chem, Ltd. Use of caspase inhibitor for alleviating or treating osteoarthritis
CN114763347B (zh) * 2021-01-15 2024-06-21 华东师范大学 一类用于诱导间充质干细胞向软骨分化的化合物及其应用
CN114763346B (zh) * 2021-01-15 2025-06-10 华东师范大学 一类用于诱导软骨形成的化合物及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1016623A (en) 1911-09-06 1912-02-06 Harry Haller Jr Photographic-printing device.
CH489993A (de) 1967-12-19 1970-05-15 Ciba Geigy Das Pflanzenwachstum regulierendes und phytocides Mittel
FR2059977A1 (enExample) 1969-08-14 1971-06-11 Socibre
CA1340191C (en) * 1988-06-13 1998-12-15 Katsuhiro Imaki Derivatives of p-substituted phenyl ester of pivalic acid
JPH0320253A (ja) * 1988-06-13 1991-01-29 Ono Pharmaceut Co Ltd ピバル酸 p―置換フェニルエステル誘導体、それらの製造方法およびそれらを有効成分として含有するエラスターゼ阻害剤
JPH0959236A (ja) 1995-08-23 1997-03-04 Dai Ichi Seiyaku Co Ltd ベンズアミド化合物
US5729014A (en) 1996-07-11 1998-03-17 Varian Associates, Inc. Method for injection of externally produced ions into a quadrupole ion trap
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
IL132991A (en) 1997-05-22 2005-11-20 Searle & Co Substituted pyrazoles, pharmaceutical compositionscomprising them and their use as p38 inase inhibi tors
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6632961B1 (en) 1998-05-22 2003-10-14 Abbott Laboratories Antiangiogenic drug to treat cancer, arthritis and retinopathy
JP2004523534A (ja) 2000-12-20 2004-08-05 ブリストル−マイヤーズ スクイブ カンパニー ケモカイン受容体活性調節剤としての環状誘導体
JP2005194191A (ja) * 2001-12-28 2005-07-21 Ajinomoto Co Inc 抗肥満薬、脂肪肝治療薬
EP1483241A4 (en) * 2002-03-08 2006-12-13 Bristol Myers Squibb Co CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
US7288538B2 (en) 2003-02-20 2007-10-30 Encysive Pharmaceuticals, Inc. Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
JP4731468B2 (ja) 2003-05-12 2011-07-27 ファイザー・プロダクツ・インク P2x7受容体のベンズアミド阻害剤
CA2533846C (en) * 2003-07-29 2012-08-28 Universitaetsklinikum Muenster Means and methods for treating a disease which is associated with an excess transport of hyaluronan across a lipid bilayer
US7863317B2 (en) 2003-08-21 2011-01-04 Bristol-Myers Squibb Company Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US7776869B2 (en) * 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
NZ555326A (en) * 2004-12-07 2010-01-29 Toyama Chemical Co Ltd Novel anthranilic acid derivative or salt thereof
KR100787131B1 (ko) 2006-07-04 2007-12-21 한국생명공학연구원 Hif―1 활성을 저해하는 화합물, 이의 제조방법 및이를 유효성분으로 함유하는 약학적 조성물
US8569378B2 (en) 2007-07-20 2013-10-29 Toshiyuki Sakai p27 protein inducer
WO2009043495A1 (en) * 2007-10-05 2009-04-09 Sanofi-Aventis Deutschland Gmbh Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain
US8143269B2 (en) 2008-10-03 2012-03-27 Calcimedica, Inc. Inhibitors of store operated calcium release
BR112012000914B8 (pt) 2009-07-14 2021-05-25 Irm Llc uso de polipeptídeo com atividade condrogênica, método in vitro de indução da diferenciação de células-tronco mesenquimais em condrócitos, e composição farmacêutica para aplicação intra-articular
MX2012013574A (es) * 2010-05-26 2013-01-24 Bayer Ip Gmbh El uso de estimuladores de la sgc, activadores de la sgc, solos y en combinacion con inhibidores de la pde5 para el tratamiento de esclerosis sistemica (ecs).
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US9452170B2 (en) 2013-03-15 2016-09-27 The California Institute For Biomedical Research Compounds and methods for inducing chondrogenesis
MX377796B (es) 2014-05-13 2025-03-11 Novartis Ag Compuestos y composiciones para inducir condrogenesis.

Similar Documents

Publication Publication Date Title
JP2016519659A5 (enExample)
IL275348B2 (en) Carbamoyl cyclohexyl acids linked via n triazole as lpa antagonists
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
JP2015537020A5 (enExample)
MY194087A (en) Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament
EP4442695A3 (en) 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders
MX2018004364A (es) Acidos pirazolo [3,4-b] piridin-6-carboxilicos sustituidos y su uso.
PE20191744A1 (es) Derivados de tirosinamida como inhibidores de rho-quinasa
DOP2013000191A (es) Derivados de heteroarilo como modulares de nachr alfa 7
WO2012122340A8 (en) Soluble guanylate cyclase activators
BR112014029016A2 (pt) derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral
IN2014CN03803A (enExample)
NZ721645A (en) Compounds for use as gpr120 agonists
CL2016000816A1 (es) Forma de dosificación que comprende al compuesto (s)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona, una cantidad de 90 hasta 99,9 por ciento en peso del peso total de una mezcla de almidón y lactosa como portador o excipiente, y acido esteárico como lubricante; su uso en el tratamiento de cáncer y enfermedades autoinmunes, entre otras.
BR112014008412A2 (pt) derivados de pirimidin-4-ona e sua utilização no tratamento, na melhora ou na prevenção de uma doença viral
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
BR112022001568A2 (pt) Composto, método para preparação do composto, composição farmacêutica, e, uso do composto
PH12013501117A1 (en) Novel compound and medical use thereof
JP2015502371A5 (enExample)
UY32435A (es) 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona útil en el tratamiento de enfermedades pulmonares
NI200900161A (es) Sales de adición de ácido, hidratos y polimorfos de la etil - amida del ácido 5 - (2,4 -dihidroxi -5- isopropil - fenil) -4- (4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas.
UY28896A1 (es) Formulaciones en polvo para la inhalación , las cuales contienen beta-agonistas enantioméricamente puros
MX2020002432A (es) Composicion farmaceutica.
MX2022011242A (es) Inmunomodulación de o-het/aril azálidos.
CL2021000627A1 (es) Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular